['diabetic kidney disease']
['selonsertib', 'placebo to match selonsertib']

        Key Inclusion Criteria:

          -  Adult male or females with prior diagnosis of Diabetic Kidney Disease

          -  Type 2 diabetes mellitus diagnosis for at least 6 months

          -  eGFR (MDRD) at screening ≥ 15 mL/min/1.73m^2 to < 60 mL/min/1.73m^2

          -  Urine albumin to creatinine ratio (UACR) as follows:

               -  Stage/Stratum 3a: eGFR range 45 to < 60 mL/min; UACR ≥ 600 mg/g

               -  Stage/Stratum 3b: eGFR range 30 to < 45 mL/min; UACR ≥ 300 mg/g

               -  Stage/Stratum 4: eGFR range 15 to < 30 mL/min; UACR ≥ 150 mg/g

          -  Receiving angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor
             blockers (ARB) at a minimum dose deemed appropriate for the individual by the
             investigator and be at a stable dose for the last three months

               -  Individuals not on ACEi/ARB may be screened if there is documented intolerance to
                  ACE inhibitor and/or ARB

        Key Exclusion Criteria:

          -  Type 1 diabetes mellitus

          -  HbA1c > 9.5%

          -  Non-diabetic kidney disease

          -  UACR > 5000 mg/g on any measurement during screening

          -  End stage renal disease (ESRD; receiving peritoneal dialysis, hemodialysis, or status
             post renal transplantation) or anticipated to occur within the treatment period

          -  Unstable cardiovascular disease

          -  Pregnant or lactating females

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      